Drug intelligence / Profile preview

BA2168

Development stage: Preclinical
Lead developer: T-Cypher Bio
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BA2168 is a bispecific T cell engager (TCE) currently in lead optimization by T-Cypher Bio for the treatment of various solid tumors. The molecule is designed to simultaneously bind to the tumor-associated antigen TC168 and the CD3 receptor on T cells, thereby recruiting and activating T cells to specifically eliminate TC168-expressing cancer cells. Its development targets a broad range of indications, including microsatellite stable colorectal cancer (MSS CRC), gastric, esophageal, lung, bladder, and pancreatic cancers, as well as melanoma and head and neck squamous cell carcinoma (HNSCC).

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on BA2168.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BA2168.